Search clinical trials for: non-small cell lung carcinoma

Total 116355 results

University Hospital Ostrava

Recruiting

Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Czechia
Guy's and St Thomas' NHS Foundation Trust
NanoMab Technology (UK) Limited

Recruiting

PD-L1 Expression in Cancer (PECan Study). (PECan)

Melanoma | Non-small Cell Lung Cancer

United Kingdom
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Hepatocellular Carcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer

Korea, Republic of, United States, Singapore
Hunan Province Tumor Hospital

Recruiting

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC (CONFIRM)

Non-small Cell Lung Cancer

China
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Shanghai Jiao Tong University School of Medicine
Shanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... and other collaborators

Recruiting

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)

Recurrent Non-small Cell Lung Cancer

China
University of Colorado, Denver
National Cancer Institute (NCI)

Recruiting

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Head and Neck Cancer | Esophageal Cancer | Lung Cancer | Precancerous Condition

United States
Massachusetts General Hospital
National Cancer Institute (NCI)

Recruiting

DNA Analysis of Blood and Tissue From Patients With Lung Cancer

Lung Cancer

United States
NYU Langone Health

Recruiting

Lung Cancer Biomarkers and Screening (NYULCBC)

Lung Cancer

United States
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)

Non-small Cell Lung Cancer

Canada, Netherlands, Spain, France, Japan, Russian Federation, Germany, Belgium, Greece, Turkey, Taiwan, United States
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Surveillance of Tabrecta Tablets

Non-small Cell Lung Cancer

Japan
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Jinling Hospital, China

Completed

A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer

Lung Cancer, Nonsmall Cell

China
University of Southern Denmark
Odense University Hospital; University of Copenhagen; Region of Southern Denmark and other collaborators

Active, not recruiting

LIFE - Lung Cancer, Immunotherapy, Frailty, Effect

Quality of Life | Venous Thromboembolism | Non-small Cell Lung Cancer | Brain Metastases

Denmark
Abramson Cancer Center at Penn Medicine
Pfizer; Lung Cancer Research Foundation

Active, not recruiting

Implementation Strategies for Monitoring Adherence in Real Time (iSMART)

Lung Cancer | Medication Adherence | Symptoms and Signs

United States
AbbVie

Active, not recruiting

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Advanced Solid Tumors

United States, Australia, Canada, Israel, Japan, Korea, Republic of, Netherlands, Puerto Rico, Spain, Taiwan
Pfizer

Active, not recruiting

PF-07284892 in Participants With Advanced Solid Tumors

Solid Tumor

United States
Pfizer

Active, not recruiting

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Netherlands, Korea, Republic of, Italy
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Pfizer

Terminated

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Non-Small Cell Lung Cancer | Urothelial Cancer

Korea, Republic of, United States, Taiwan, Poland, Spain, Russian Federation, Italy, Hungary
Pfizer

Active, not recruiting

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Taiwan, Australia, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Melanoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Bone Cancer | Rectal Cancer | Uterine Sarcoma | Colon Cancer | Ovarian Sarcoma | Eye Cancer | Adult Soft Tissue Sarcoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage II Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage I Pancreatic Cancer | Stage II Non-small Cell Lung Cancer | Stage III Colon Cancer and other conditions

United States
Immatics US, Inc.
M.D. Anderson Cancer Center

Completed

ACTolog in Patients With Solid Cancers (ACTolog)

Cancer | Solid Tumor

United States
Guangdong Association of Clinical Trials

Active, not recruiting

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC (FLOWERS)

Carcinoma, Non-Small-Cell Lung

China
AstraZeneca
Parexel; Iqvia Pty Ltd; Medidata Solutions; CISCRP

Active, not recruiting

Durvalumab Long-Term Safety and Efficacy Study (WAVE)

Solid Tumor

Spain, United Kingdom, United States, Canada, Czechia, Poland, Romania, Thailand, Vietnam, Belgium, France, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Malaysia, Taiwan, Australia, Germany, Turkey, Ukraine, Nethe... and more
JS InnoPharm, LLC

Suspended

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Solid Tumors

United States
Institut Bergonié

Active, not recruiting

Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients (OPTIMUNELUNG)

Non Small Cell Lung Cancer

France
Incyte Corporation
AstraZeneca

Active, not recruiting

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Lung Cancer

United States, Korea, Republic of, Spain, Taiwan
Swiss Group for Clinical Cancer Research

Active, not recruiting

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Non-small Cell Lung Cancer | Malignant Pleural Mesothelioma

Switzerland
University of Texas Southwestern Medical Center

Completed

Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Deciphera Pharmaceuticals LLC

Completed

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Gastrointestinal Stromal Tumors | Advanced Cancers | Advanced Systemic Mastocytosis

United States, Canada, Germany, Italy, Netherlands, United Kingdom
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

Pancreatic Cancer | Malnutrition | Lung Cancer | Prostate Cancer | Weight Changes

United States
Fate Therapeutics

Terminated

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Sun Yat-sen University

Completed

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (AdvanTIG-306)

Non-small Cell Lung Cancer (NSCLC)
Incyte Corporation

Completed

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Metastatic Melanoma | Unresectable Melanoma | Metastatic Urothelial Cancer | Metastatic Non-small Cell Lung Cancer | Locally Advanced Renal Cell Carcinoma | Locally Advanced Urothelial Cancer | Metastatic Clear-Cell Renal Cell Carcinoma

France, Spain, United States, Italy, Austria, Romania, Poland, Hungary
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
AstraZeneca

Completed

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies | Non-Small Cell Lung Cancer (NSCLC) | Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) | Colorectal Carcinoma (CRC)

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; AIDS and Cancer Specimen Resource

Terminated

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

Lymphoma | Lung Cancer

United States
First Affiliated Hospital of Zhejiang University

Terminated

Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Non Small Cell Lung Cancer

China
Rain Oncology Inc

Terminated

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (TH-4000)

NSCLC | Non-small Cell Lung Cancer | Non-squamous NSCLC

United States, Australia

Search clinical trials for: non-small cell lung carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations